M
Moleculent
Developing a functional profiling platform that allows scientists to map cell-cell communication directly in clinical tissue, providing insights to accelerate the functional understanding of biology
About Moleculent
Moleculent is a life sciences company that has developed a functional biology platform to detect and profile cell-cell interactions and communication directly within the tissue environment. This technology provides researchers with a novel approach to understanding the mechanisms of disease by observing how cells communicate with each other in their native settings.
Read full description
The company's platform is designed to help scientists differentiate between the functioning of healthy and diseased cells, with a particular focus on applications in cancer research, such as melanoma. By mapping these cellular conversations, Moleculent aims to provide critical insights that can accelerate the development of new therapeutic strategies.
The company recently secured $26 million in Series A financing, which will be used to advance the spatial mapping of cell-cell communication and expand its research and development efforts. Moleculent's primary clients are researchers in academic institutions, pharmaceutical companies, and biotechnology firms engaged in cellular biology and drug discovery.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Stockholm, Sweden
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 93.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Tech for Biotech and Pharma, Techbio, Techbio Drug Discovery, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Moleculent.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2026 | $20M | $130M | Rubicon Healthcare Partners · ARCH Venture Partners · Eir Ventures | ↗ |
| SERIES A✓Equity / VC | Jun 2024 | $26M | $104M | ARCH Venture Partners · Eir Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Moleculent is 4.7K monthly website visits, up 1136.8% over the last three months. Moleculent's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
ARCH Venture Partners
Eir Ventures
Rubicon Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Moleculent on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Moleculent’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.